Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
30 05 2019
Historique:
received: 16 10 2018
accepted: 25 03 2019
pubmed: 29 3 2019
medline: 24 12 2019
entrez: 29 3 2019
Statut: ppublish

Résumé

Heparin-induced thrombocytopenia (HIT) is due to immunoglobulin G (IgG) antibodies, which bind platelet factor 4 (PF4) modified by polyanions, such as heparin (H). IgG/PF4/polyanion complexes directly activate platelets via Fc gamma type 2 receptor A (FcγRIIA) receptors. A bacterial protease, IgG-degrading enzyme of

Identifiants

pubmed: 30917957
pii: S0006-4971(20)42520-0
doi: 10.1182/blood.2019000437
doi:

Substances chimiques

Bacterial Proteins 0
FCGR2A protein, human 0
Immunoglobulin G 0
Mac-1-like protein, Streptococcus 0
Receptors, IgG 0
Platelet Factor 4 37270-94-3
Fibrin 9001-31-4
Heparin 9005-49-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2427-2435

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 by The American Society of Hematology.

Auteurs

Claire Kizlik-Masson (C)

EA 7501, Innovation and Cell Targeting Group, Université de Tours, Tours, France.

Quentin Deveuve (Q)

EA 7501, Innovation and Cell Targeting Group, Université de Tours, Tours, France.

Yuhang Zhou (Y)

Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA.

Caroline Vayne (C)

EA 7501, Innovation and Cell Targeting Group, Université de Tours, Tours, France.
Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA.
Laboratoire d'Hématologie-Hémostase and.

Gilles Thibault (G)

EA 7501, Innovation and Cell Targeting Group, Université de Tours, Tours, France.
Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA.
Laboratoire d'Hématologie-Hémostase and.
Laboratoire d'Immunologie, Centre Hospitalier Régional Universitaire de Tours, Tours, France; and.

Steven E McKenzie (SE)

Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA.

Claire Pouplard (C)

EA 7501, Innovation and Cell Targeting Group, Université de Tours, Tours, France.
Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA.
Laboratoire d'Hématologie-Hémostase and.

Stéphane Loyau (S)

Laboratory of Vascular Translational Science, U1148, INSERM and University Paris Diderot, Paris, France.

Yves Gruel (Y)

EA 7501, Innovation and Cell Targeting Group, Université de Tours, Tours, France.
Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA.
Laboratoire d'Hématologie-Hémostase and.

Jérôme Rollin (J)

EA 7501, Innovation and Cell Targeting Group, Université de Tours, Tours, France.
Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA.
Laboratoire d'Hématologie-Hémostase and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH